RecoveryFDA Approved

OP-1 / BMP-7

Implantation at surgical site

Overview

OP-1, or osteogenic protein-1, is the recombinant form of bone morphogenetic protein-7 (BMP-7), a member of the transforming growth factor-beta superfamily. This homodimeric protein induces differentiation of mesenchymal stem cells into osteoblasts and chondrocytes, stimulating new bone formation.

Mechanism of Action

It was developed primarily for spinal fusion procedures and long bone non-unions where autologous bone graft is not feasible..

Research Summary & Key Findings

OP-1 received a Humanitarian Device Exemption from the FDA in 2001 for use in recalcitrant long bone non-unions. Clinical trials in tibial non-union demonstrated healing rates comparable to autograft in selected populations, though the product was withdrawn from the U.S. market in 2014 due to commercial considerations.

Clinical Status

FDA Approved

OP-1 / BMP-7 has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Implantation at surgical site

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers OP-1 / BMP-7 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply OP-1 / BMP-7.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.